Blue Cross and Blue Shield of Minnesota on Thursday sued disgraced pharmaceutical executive Martin Shkreli and his company Vyera Pharmaceuticals over an alleged price-fixing scheme, in what attorneys for the state’s leading health plan said was the first private lawsuit to stem from a sudden and dramatic increase in the cost of a lifesaving drug in 2014.

The 128-page lawsuit, filed in Manhattan federal court, alleged that Shkreli and his former business partner Kevin Mulleady pocketed millions of dollars at the expense of a class of health plans by driving up the price of Daraprim by more than 4,000% overnight and blocking the development of lower-cost generics.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]